Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 10:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hyperlipoproteinemias Clear all
Terminated Phase 2 Interventional

Implitapide in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) on Maximal Concurrent Lipid-Lowering Therapy

NCT00079859
View directory record Official record
Conditions
Familial Hypercholesterolemia
Interventions
Implitapide
Drug
Lead sponsor
Medical Research Laboratories International
Industry
Eligibility
18 Years to 70 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 23, 2026, 10:55 AM EDT
Completed Phase 1 Interventional

The Effects of a Mediterranean Diet in Pediatric Hyperlipidemia

NCT01308710
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Omega-3 fatty acid (Eicosapentaenoic acid)
Dietary Supplement
Lead sponsor
University of California, San Francisco
Other
Eligibility
8 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2014 · Synced Jul 23, 2026, 10:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Healthy Volunteers Study of the Effects of Olanzapine and Ziprasidone

NCT00910988
View directory record Official record
Conditions
Hyperglycemia, Hyperlipidemia
Interventions
Olanzapine, Ziprasidone
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Jul 23, 2026, 10:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect Of Capros Supplementation On Cardiovascular Disease Risk Factors In Humans

NCT01858376
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Capros dietary supplement
Dietary Supplement
Lead sponsor
Chandan K Sen
Other
Eligibility
21 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Jul 23, 2026, 10:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cardiovascular Risk Assessment for Patients With Rheumatoid Arthritis Arthritis:

NCT04488497
View directory record Official record
Conditions
Rheumatoid Arthritis, Cardiovascular Diseases, Hyperlipidemias
Interventions
Cardiovascular Risk Assessment for Patients with Rheumatoid Arthritis, Standard of care
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
40 Years to 75 Years
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Jul 23, 2026, 10:55 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Effect of Pterostilbene on Cholesterol, Blood Pressure and Oxidative Stress

NCT01267227
View directory record Official record
Conditions
Hyperlipidemia, Blood Pressure, Oxidative Stress
Interventions
Pterostilbene 50 mg twice daily, Placebo, Grape Extract, Pterostilbene 125 mg twice daily
Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years to 88 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced Jul 23, 2026, 10:55 AM EDT
Completed Phase 4 Interventional Results available

A Prospective, Open Label Comparison of Ezetimibe, Niacin, and Colestipol as Adjunct Therapy in Lipid Reduction

NCT00203476
View directory record Official record
Conditions
Hyperlipidemia, Hypercholesterolemia
Interventions
Niacin, Colestipol, Ezetimibe
Drug
Lead sponsor
Tuscaloosa Research & Education Advancement Corporation
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Tuscaloosa, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 11, 2014 · Synced Jul 23, 2026, 10:55 AM EDT
Completed Phase 4 Interventional Results available

Prevail-Us: A Study Of Pitavastatin 4 mg Vs. Pravastatin 40 mg In Patients With Primary Hyperlipidemia Or Mixed Dyslipidemia

NCT01256476
View directory record Official record
Conditions
Primary Dyslipidemia, Mixed Dyslipidemia
Interventions
pitavastatin, pravastatin
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
44
States / cities
Huntsville, Alabama • Muscle Shoals, Alabama • Chandler, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated May 7, 2012 · Synced Jul 23, 2026, 10:55 AM EDT
Completed Phase 2 Interventional

Study of the Safety and Tolerability Associated With PPD10558 Versus Atorvastatin in Patients Previously Intolerant to Statins Due to Statin-associated Myalgia (SAM)

NCT01279590
View directory record Official record
Conditions
Myalgia, Hypercholesterolemia, Hyperlipidemia
Interventions
PPD10558, Atorvastatin, Placebo
Drug
Lead sponsor
Furiex Pharmaceuticals, Inc
Industry
Eligibility
40 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
67
States / cities
Anniston, Alabama • Phoenix, Arizona • Huntington Park, California + 60 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2011 · Synced Jul 23, 2026, 10:55 AM EDT
Completed Phase 2 Interventional Results available

Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease

NCT00296374
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Rosuvastatin, Atorvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
29
States / cities
Avondale, Arizona • Phoenix, Arizona • Jonesboro, Arkansas + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2011 · Synced Jul 23, 2026, 10:55 AM EDT
Completed Phase 3 Interventional Results available

Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia

NCT01854918
View directory record Official record
Conditions
Hyperlipidemia and Mixed Dyslipidemia
Interventions
Evolocumab, Standard of Care
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 85 Years
Enrollment
3,681 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
107
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 94 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Jul 23, 2026, 10:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study Of Nutraceutical Drinks For Cholesterol (Evaluating Effectiveness and Tolerability)

NCT01152073
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Placebo, Second Formulation, Third Formulation
Dietary Supplement
Lead sponsor
Healthy Drink Discoveries, Inc.
Other
Eligibility
20 Years to 80 Years
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Jul 23, 2026, 10:55 AM EDT
Completed Phase 3 Interventional Results available

Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C

NCT03814187
View directory record Official record
Conditions
ASCVD, Elevated Cholesterol, Heterozygous Familial Hypercholesterolemia, Homozygous Familial Hypercholesterolemia
Interventions
Inclisiran Sodium
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
3,275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
141
States / cities
Birmingham, Alabama • Foley, Alabama • Huntsville, Alabama + 109 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Jul 23, 2026, 10:55 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Stop Atherosclerosis in Native Diabetics Study

NCT00147251
View directory record Official record
Conditions
Cardiovascular Disease, Hypertension, Hyperlipidemia, Diabetes, Carotid Atherosclerosis
Interventions
FDA approved drugs to treat blood pressure and cholesterol
Drug
Lead sponsor
Cynthia West
Other
Eligibility
40 Years and older
Enrollment
548 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
4
States / cities
Chinle, Arizona • Phoenix, Arizona • Lawton, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Jul 23, 2026, 10:55 AM EDT
Completed Phase 2 Interventional Results available

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects

NCT01375764
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Evolocumab, Ezetimibe, Placebo to Evolocumab
Biological · Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
16
States / cities
Anaheim, California • Mission Viejo, California • Westlake Village, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2022 · Synced Jul 23, 2026, 10:55 AM EDT
Completed Not applicable Interventional

HeartBeet Clinic Pilot Trial

NCT06486532
View directory record Official record
Conditions
Hyperlipidemia, Hypertension
Interventions
HeartBeet Clinic, Self-paced education
Behavioral
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Saint Louis Park, Minnesota
Source: ClinicalTrials.gov public record
Updated May 10, 2025 · Synced Jul 23, 2026, 10:55 AM EDT
Completed Phase 3 Interventional

Effect of Lapaquistat Acetate on Blood Cholesterol Levels in Subjects With Elevated Cholesterol

NCT00143663
View directory record Official record
Conditions
Dyslipidemia
Interventions
Lapaquistat Acetate, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
47
States / cities
Northport, Alabama • Mesa, Arizona • Chula Vista, California + 44 more
Source: ClinicalTrials.gov public record
Updated May 23, 2012 · Synced Jul 23, 2026, 10:55 AM EDT
Completed Phase 2 Interventional

Effects of Resistance and Aerobic Exercise on Cardiovascular Health

NCT00275145
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Obesity, Hyperlipidemia, Insulin Resistance, Metabolic Syndrome X
Interventions
Resistance Training, Aerobic Exercise, Combo, Continued Sedentary lifestyle
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 70 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 23, 2013 · Synced Jul 23, 2026, 10:55 AM EDT
Completed No phase listed Observational

Hearing Loss and the Effects of Statin Drugs in People With Head and Neck Squamous Cell Carcinoma Treated With Cisplatin Chemoradiation

NCT03225157
View directory record Official record
Conditions
Head and Neck Neoplasms, Hearing Disorder, Hyperlipidemia
Interventions
Not listed
Lead sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
NIH
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Jul 23, 2026, 10:55 AM EDT
Completed Phase 3 Interventional

The Health Outcomes Management and Evaluation (HOME) Study

NCT01228032
View directory record Official record
Conditions
Diabetes, Hyperlipidemia, Heart Disease, High Blood Pressure
Interventions
Care team
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Marietta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 25, 2016 · Synced Jul 23, 2026, 10:55 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Serum Lipid Levels and Other Biomarkers of Cardiovascular Disease in Patients With Psoriasis

NCT01019200
View directory record Official record
Conditions
Psoriasis, Cardiovascular Diseases, Dyslipidemia
Interventions
Not listed
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 80 Years
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 15, 2016 · Synced Jul 23, 2026, 10:55 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Antidiabetic Medications on the Postprandial State in Prediabetes

NCT02104739
View directory record Official record
Conditions
Prediabetes, Obesity
Interventions
Exenatide, Saxagliptin, Exenatide extended-release (ER), Placebo
Drug · Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
30 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Jul 23, 2026, 10:55 AM EDT
Completed Not applicable Interventional Results available

Evaluation of Pharmacist Interventions in Lipid Management for Secondary Prevention

NCT06647238
View directory record Official record
Conditions
Hyperlipidemia, Coronary Artery Disease
Interventions
Pharmacist Intervention in lipid therapy
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Concord, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 21, 2025 · Synced Jul 23, 2026, 10:55 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluation of 3-V Bioscience-2640 to Reduce de Novo Lipogenesis in Subjects With Characteristics of Metabolic Syndrome

NCT02948569
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
3-V Bioscience-2640
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
35 Years to 60 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated May 3, 2025 · Synced Jul 23, 2026, 10:55 AM EDT